Stryker's Q2 Rebound Tempers Sell Signal but Valuation Remains Stretched

What happened

Stryker delivered 9% organic growth in Q2 2025, with both MedSurg & Neurotech and Orthopaedics segments accelerating sharply, suggesting the Q1 slowdown was temporary. Guidance was modestly adjusted upward, and demand remains broad-based, but the report's prior 'potential sell' stance was driven by rich valuation at ~46x earnings and a DCF value near $124 versus a $352 share price. The article's claim of a better entry point after the sell-off is questionable given that the stock still trades far above intrinsic value despite a slight de-rating over 12 months. Tariff headwinds (~$175-200mn), integration risks from recent acquisitions (Inari, care.ai, NICO), and competitive pressure in robotics remain unresolved. While the Q2 rebound is encouraging, the margin of safety remains thin, and any disappointment in growth or margins could trigger further multiple compression.

Implication

1. The Q2 recovery reduces near-term downside pressure but does not change the fundamental issue: Stryker trades at a premium that prices in flawless execution and sustained double-digit growth. 2. Investors should focus on signs that the acceleration is durable, such as Mako installs, Inari integration, and margin resilience against tariffs, rather than extrapolating one quarter. 3. A failure to sustain organic growth above high-single digits or any additional goodwill impairments would likely de-rate the stock sharply toward the DCF-based value. 4. Conversely, if management delivers on guidance and shows that the Q2 rebound is the start of a trend, the premium multiple may be justified, but the risk-reward is unattractive at current levels. 5. We advise trimming into strength or waiting for a lower entry point, as the article's enthusiasm for a better entry point may be premature given the disconnect between price and intrinsic value.

Thesis delta

The Q2 rebound shifts the stance from 'potential sell' to 'hold/wait' as near-term demand fundamentals improved. However, the core thesis of overvaluation remains intact; the stock still trades at ~46x earnings versus a DCF value near $124, leaving little room for error. Thus, we move from a sell bias to a neutral hold, but would turn more positive only if the stock de-rates toward intrinsic value or if growth proves sustainably stronger than expected.